Dramatic progress has been made recently in diagnosing and treating herpes simplex virus encephalitis (HSVE). Advances in imaging technology have greatly enhanced our ability to diagnose the illness noninvasively. Acyclovir is of proven efficacy and is generally well-tolerated. The major clinical management problem is that the pathologic process in the brain is usually well-advanced before the patient presents, and the symptoms, particularly in newborns or infants, are often initially nonspecific. This, plus a too frequent failure to recognize the nature and seriousness of the process, results in further delay in diagnosis and treatment. Physicians need to develop an increased awareness of the early signs and symptoms of the presentation of HSVE, and of the imperative for early treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ncl.2008.03.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Wolf's Isotopic Response: Acquired Arteriovenous Haemangioma Following Oral Herpes Simplex Virus Infection.
Australas J Dermatol
January 2025
Department of Dermatology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Cutaneous arteriovenous haemangioma (AVH) is a rare benign vascular lesion, which typically occurs on the head and neck. Its aetiology is unclear but thrombosis, trauma, infection or endocrine triggers have been proposed. We report the case of a 64-year-old female presenting with acquired AVH of the upper lip following oral herpes simplex virus infection.
View Article and Find Full Text PDFNucleoside antiviral agents with atypical structures and new targets.
Bioorg Med Chem Lett
January 2025
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, China. Electronic address:
Nucleoside analogs (NAs), as antiviral drugs, play a significant role in clinical medicine, constituting approximately 50 % of all antiviral therapies in current use. Nucleoside inhibitors function by mimicking the structure of natural nucleosides, integrating themselves into viral genetic material during replication, and subsequently inhibiting the virus's ability to reproduce. They are used to treat a variety of viral infections, including herpes simplex, hepatitis B, and acquired immunodeficiency syndrome (AIDS).
View Article and Find Full Text PDF[Herpetic esophagitis: report of a case].
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
Novel Hsp90α inhibitor inhibits HSV-1 infection by suppressing the Akt/β-catenin pathway.
Int J Antimicrob Agents
January 2025
School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China. Electronic address:
The prevalence of herpes simplex virus type 1 (HSV-1) infection and the emergence of drug-resistant HSV-1 strains posts a significant global health challenge, necessitating the urgent development of effective anti-HSV-1 drugs. As one of the most prevalent molecular chaperones, heat shock protein 90 α (Hsp90α) has been extensively demonstrated to regulate a range of viral infections, thus representing a promising antiviral target. In this study, we identified JD-13 as a novel Hsp90α inhibitor and explored its capability in inhibiting HSV-1 infection.
View Article and Find Full Text PDFHerpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review.
Viruses
January 2025
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
In this narrative review, we explore the burden and risk factors of various herpesvirus infections in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAb) for the treatment of hematologic malignancies. Antiviral prophylaxis for herpes simplex/varicella zoster viruses became part of the standard of care in this patient population. Breakthrough infections may rarely occur, and the optimal duration of prophylaxis as well as the timing of recombinant zoster immunization remain to be explored.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!